<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151944</url>
  </required_header>
  <id_info>
    <org_study_id>SPD476-303</org_study_id>
    <secondary_id>2004-000734-36</secondary_id>
    <nct_id>NCT00151944</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.</brief_title>
  <official_title>A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the long-term safety and tolerability of SPD476 in the
      maintenance of ulcerative colitis remission.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment emergent adverse events over 12 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject compliance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects in remission after 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UC-DAI score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient questionnaire</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD476 (mesalazine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have completed all assessments of SPD476-301 or SPD476-302 End of
             Study/Early Withdrawal Visit

          -  Subjects who did not achieve remission at the End of Study/Early Withdrawal Visits in
             Study 301 or 302 will be eligible to enter the Acute Phase; subjects who did achieve
             remission at the End of Study Visits in Study 301 or 302 will be eligible to enter
             directly into the Maintenance Phase

          -  Women of childbearing potential must use an acceptable contraceptive method while on
             study treatment

        Exclusion Criteria:

          -  Subjects who withdrew from Study 301 or 302 before Study Visit 3, or who withdrew due
             to a possible or probably related severe adverse event or serious adverse event are
             not eligible to enter this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall information</description>
  </link>
  <results_reference>
    <citation>Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008 Jul;57(7):893-902. doi: 10.1136/gut.2007.138248. Epub 2008 Feb 13.</citation>
    <PMID>18272546</PMID>
  </results_reference>
  <results_reference>
    <citation>Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan;15(1):1-8. doi: 10.1002/ibd.20580.</citation>
    <PMID>18671232</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

